Chronic Smell and Flavor Loss Therapeutics Market in the 7MM is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Chronic Smell and Flavor Loss Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of chronic smell and flavor loss, historical and forecasted epidemiology, as well as the chronic smell and flavor loss market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Chronic Smell and Flavor Loss Market with DelveInsight's In-Depth Report @ Chronic Smell and Flavor Loss Market Size [https://www.delveinsight.com/sample-request/chronic-smell-and-flavor-loss-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Smell and Flavor Loss Market Report

* According to DelveInsight's epidemiology model, in the US, the total prevalent cases of Chronic Smell and Flavor Loss were approximately 86 million in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in testing.
* Among the diagnosed prevalent cases of Chronic Smell and Flavor Loss in EU4 and the UK in 2023, the highest cases were observed in Germany which was approximately 11 million cases and the least number of diagnosed cases were in Spain with approximately 5 million.
* In 2023, gender-specific instances (excluding COVID-19 patients) of Chronic Smell and Flavor Loss were seen to be more in females with around 2.2 million cases as compared to males which were around 1.8 million in the UK.
* According to DelveInsight's epidemiology model, age-specific cases of Chronic Smell and Flavor Loss in the US for 2023 were segmented into the age groups of 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older. The highest prevalence was observed in the 70-79 years age group.
* In 2023, Japan reported 1.6 million cases of Chronic Smell and Flavor Loss due to post-influenza hyposmia and hypogeusia, alongside 1.7 million cases attributed to other causes.
* The leading Chronic Smell and Flavor Loss Companies such as Cyrano Therapeutics, Johns Hopkins, MSD Manual, Alcon, Stanford Medicine, Immunomic Therapeutics, Siemens Healthcare Pvt Ltd, Omega Diagnostic Group PLC, HYCOR Biomedical , and others.
* Promising Chronic Smell and Flavor Loss Therapies such as CYR-064 , and others.

Stay ahead in the Chronic Smell and Flavor Loss Therapeutics Market with DelveInsight's Strategic Report @ Chronic Smell and Flavor Loss Market Outlook [https://www.delveinsight.com/sample-request/chronic-smell-and-flavor-loss-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Smell and Flavor Loss Epidemiology Segmentation in the 7MM

* Total Chronic Smell and Flavor Loss Prevalent Cases
* Total Chronic Smell and Flavor Loss Diagnosed Cases
* Chronic Smell and Flavor Loss Gender-specific Diagnosed Cases (excluding COVID-19 patients)
* Chronic Smell and Flavor Loss Age-specific Diagnosed Cases (excluding COVID-19 patients)
* Chronic Smell and Flavor Loss Etiology-specific Cases (excluding COVID-19 patients)

Download the report to understand which factors are driving Chronic Smell and Flavor Loss epidemiology trends @ Chronic Smell and Flavor Loss Prevalence [https://www.delveinsight.com/sample-request/chronic-smell-and-flavor-loss-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Smell and Flavor Loss Emerging Drugs Profile

* CYR-064: Cyrano Therapeutics

CYR-064, developed by Cyrano Therapeutics, is an innovative nasal spray designed to restore olfactory and gustatory function in individuals with chronic sensory loss. This formulation utilizes phosphodiesterase (PDE) inhibitors for intranasal delivery, targeting the mechanisms underlying smell and flavor loss. These conditions typically inhibit stem cell activation mediated by adenylyl cyclase III through cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), reducing growth factor secretion from nasal mucus and impairing stem cell activity in the olfactory epithelium. By delivering PDE inhibitors directly to this region, cAMP and cGMP levels can be increased, potentially restoring olfactory function. Clinical experience has shown that various PDE inhibitors can correct smell loss and, in some cases, restore olfactory function to near-normal levels. CYR-064 is currently in Phase II clinical trials specifically targeting hyposmia, with promising implications for improving outcomes in affected patients.

Chronic Smell and Flavor Loss Treatment Market

The Chronic Smell and Flavor Loss treatment involves several classes of interventions aimed at addressing the underlying causes and alleviating symptoms. Corticosteroids are commonly used to reduce inflammation in cases related to nasal pathology, enhancing olfactory function. Tricyclic antidepressants, such as amitriptyline and imipramine, are employed to manage abnormal sensations associated with taste disorders, particularly in conditions like burning mouth syndrome (BMS). Zinc supplements, specifically zinc gluconate, have shown therapeutic potential in idiopathic dysgeusia, offering a targeted approach for taste disturbances. Additionally, benzodiazepines like clonazepam and diazepam are utilized to address anxiety and discomfort associated with sensory dysfunctions. Emerging therapies and further research into neuroprotective agents may also contribute to a more comprehensive treatment landscape for these disorders.

Get In-Depth Knowledge on Chronic Smell and Flavor Loss Market Trends and Forecasts with DelveInsight @ Chronic Smell and Flavor Loss Treatment Market [https://www.delveinsight.com/sample-request/chronic-smell-and-flavor-loss-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Smell and Flavor Loss Companies

Cyrano Therapeutics, Johns Hopkins, MSD Manual, Alcon, Stanford Medicine, Immunomic Therapeutics, Siemens Healthcare Pvt Ltd, Omega Diagnostic Group PLC, HYCOR Biomedical, and others.

Chronic Smell and Flavor Loss Market Outlook

Current treatment options for olfactory and gustatory disorders are limited, primarily focusing on corticosteroids and surgical interventions for nasal pathologies, such as polypectomy and pan sinus procedures. For taste disorders, while corticosteroids and vitamin A are often considered, they lack robust clinical evidence. Zinc gluconate has shown some therapeutic effectiveness in idiopathic dysgeusia, and tricyclic antidepressants like amitriptyline and imipramine are utilized for managing burning mouth syndrome (BMS). Cyrano Therapeutics is a major player in this market with its lead product, CYR-064, which comprises phosphodiesterase (PDE) inhibitors formulated for intranasal administration. This candidate is designed to address the common mechanisms underlying smell and flavor loss by inhibiting stem cell activation. Following successful fundraising and patent approvals, Cyrano is advancing toward a Phase II clinical trial in the US. Despite the absence of other pharmaceutical companies actively developing novel treatments, ongoing trials led by universities and research organizations are exploring potential alternatives, driven by increased awareness and the pressing need for effective therapies in the context of rising cases linked to the COVID-19 pandemic.

Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Smell and Flavor Loss Market Report @ Chronic Smell and Flavor Loss Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-smell-and-flavor-loss-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chronic Smell and Flavor Loss Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Chronic Smell and Flavor Loss Companies- Cyrano Therapeutics, Johns Hopkins, MSD Manual, Alcon, Stanford Medicine, Immunomic Therapeutics, Siemens Healthcare Pvt Ltd, Omega Diagnostic Group PLC, HYCOR Biomedical, and others.
* Chronic Smell and Flavor Loss Therapies- CYR-064, and others.
* Chronic Smell and Flavor Loss Market Dynamics: Chronic Smell and Flavor Loss Market Drivers and Barriers
* Chronic Smell and Flavor Loss Unmet Needs, KOL's views, Analyst's views, Chronic Smell and Flavor Loss Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Chronic Smell and Flavor Loss Market Overview at a Glance

4 Executive Summary of Chronic Smell and Flavor Loss

5 Disease Background and Overview

6 Epidemiology and Patient Population

7 Patient Journey

8 Emerging Therapies

9 Chronic Smell and Flavor Loss: The Seven Major Market Analysis

10 SWOT Analysis

11 Unmet Needs

12 Market Access and Reimbursement

13 KOL Views

14 Acronyms and Abbreviations

15 Appendix

16 DelveInsight Capabilities

17 Disclaimer

18 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-smell-and-flavor-loss-therapeutics-market-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.